A Delaware jury ruled in June 2026 that Amgen and its subsidiary Teneobio willfully infringed Harbour BioMed's Grosveld patent, awarding Harbour US$20,203,704 in damages with the option to seek a tripling of that amount. The verdict, in one of the most closely watched antibody technology patent disputes, highlights legal and financial exposure around Amgen's antibody discovery platforms and broader IP posture. The potential US$20.2 million to US$60.6 million damages look small next to Amgen's US$37.1 billion to US$38.5 billion revenue guidance, so the near-term demand and pricing catalysts around key franchises still appear more important than this single case. However, the verdict raises fresh questions about Amgen's broader patent exposure and could lead some analysts to reassess assumptions that Amgen can keep scaling high-margin launches without higher legal and patent risk.
Amgen IncJury found Amgen willfully infringed Harbour BioMed patent, awarding damages and raising patent risk concerns.
Bank of Ningbo Co LtdTeneobio, as Amgen subsidiary, was also found to have willfully infringed the patent.